Latest research on GLP-1 efficacy, muscle preservation, and metabolic outcomes.
Recent clinical data highlights the potential of GLP-1 medications to significantly improve Obstructive Sleep Apnea (OSA) severity, expanding their role in comprehensive metabolic care.
May 27, 2026 • 5 min readExploring the profound cardiovascular and metabolic benefits of GLP-1 receptor agonists beyond weight loss.
May 27, 2026 • 7 min readRecent studies reveal that GLP-1 receptor agonists offer significant cardiovascular protection independent of weight loss, shifting the paradigm in preventative cardiology.
May 20, 2026 • 5 min readExploring the paradigm shift of GLP-1 receptor agonists from weight loss and diabetes management to potent cardiovascular risk reduction based on landmark clinical trials.
May 20, 2026 • 6 min readA clinical comparison of semaglutide and tirzepatide based on SURMOUNT-5, STEP, and SURPASS data — efficacy, tolerability, and what the receptor pharmacology tells us about who responds best.
May 13, 2026 • 7 min readEmerging research indicates that GLP-1 receptor agonists may offer neuroprotective benefits, potentially transforming how we approach cognitive preservation and neurodegenerative diseases.
May 6, 2026 • 5 min readExploring the significant cardiovascular and metabolic benefits of GLP-1 receptor agonists beyond traditional weight loss and glycemic control.
May 6, 2026 • 6 min readA new Cell Reports study demonstrates that proper protein and training protocols can preserve lean muscle mass during significant weight loss.
April 18, 2026 • 5 min readHitting a weight-loss plateau on GLP-1 medications is common. Clinical science points to comprehensive lifestyle interventions to break through.
April 26, 2026 • 6 min read